HomeCompareLTKBF vs PFE

LTKBF vs PFE: Dividend Comparison 2026

LTKBF yields 0.78% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $21.6K in total portfolio value· pulled ahead in Year 9
10 years
LTKBF
LTKBF
● Live price
0.78%
Share price
$49.90
Annual div
$0.39
5Y div CAGR
35.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$2,170.27
Full LTKBF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — LTKBF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLTKBFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LTKBF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LTKBF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LTKBF
Annual income on $10K today (after 15% tax)
$66.43/yr
After 10yr DRIP, annual income (after tax)
$1,844.73/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $20,475.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LTKBF + PFE for your $10,000?

LTKBF: 50%PFE: 50%
100% PFE50/50100% LTKBF
Portfolio after 10yr
$38.8K
Annual income
$14,214.49/yr
Blended yield
36.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

LTKBF
No analyst data
Altman Z
2.1
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LTKBF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLTKBFPFE
Forward yield0.78%6.13%
Annual dividend / share$0.39$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR35.7%13.2%
Portfolio after 10y$28.0K$49.6K
Annual income after 10y$2,170.27$26,258.71
Total dividends collected$7.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LTKBF vs PFE ($10,000, DRIP)

YearLTKBF PortfolioLTKBF Income/yrPFE PortfolioPFE Income/yrGap
1$10,806$106.06$9,153$693.39+$1.7KLTKBF
2$11,708$145.35$8,593$849.25+$3.1KLTKBF
3$12,727$199.72$8,336$1,066.78+$4.4KLTKBF
4$13,893$275.33$8,437$1,384.80+$5.5KLTKBF
5$15,247$381.18$9,013$1,875.40+$6.2KLTKBF
6$16,845$530.53$10,306$2,680.72+$6.5KLTKBF
7$18,767$743.34$12,820$4,101.38+$5.9KLTKBF
8$21,131$1,050.31$17,673$6,826.70+$3.5KLTKBF
9← crossover$24,110$1,499.82$27,543$12,591.86$3.4KPFE
10$27,968$2,170.27$49,560$26,258.71$21.6KPFE

LTKBF vs PFE: Complete Analysis 2026

LTKBFStock

Logistec Corporation, together with its subsidiaries, provides cargo handling and other services to marine, industrial, and municipal customers in Canada and the United States. It operates in two segments, Marine Services and Environmental Services. The company provides specialized cargo handling services, which include container, bulk, breakbulk, and project cargo, as well as other services through the operation of 80 terminals in 54 ports in North America. It also stevedoring, cargo loading and unloading, container stuffing and destuffing, ship dockage, road transportation, and storage services, as well as tailgating, including truck loading and discharging services; and marine agency services to foreign shipowners and operators serving the Canadian market. In addition, the company is involved in the renewal of underground water mains, dredging, dewatering, contaminated soils and materials management, site remediation, and risk assessment, as well as manufacturing of fluid transportation products. Further, it offers turnkey solutions for the environmental assessment of properties and the remediation of impacted soils, groundwater, and lagoons; and services for proper handling of hazardous materials in buildings and the replacement of underground hydrocarbon storage infrastructure, including the characterization and remediation of sites and risk assessment, as well as contaminated soils and materials management. The company was formerly known as Quebec Terminals Ltd. and changed its name to Logistec Corporation in April 1969. Logistec Corporation was incorporated in 1952 and is headquartered in Montreal, Canada.

Full LTKBF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this LTKBF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LTKBF vs SCHDLTKBF vs JEPILTKBF vs OLTKBF vs KOLTKBF vs MAINLTKBF vs JNJLTKBF vs MRKLTKBF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.